Cervical Cancer Screening and Abnormal Cervical Cytology Management
Referanslar
Republic of Turkey Ministry of Health, Public Health Directorate, Cancer Department https://hsgm.saglik.gov.tr/depo/birimler/kanserdb/Dokumanlar/Istatistikler/Kanser_Rapor_2018.pdf
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.
Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute; Bethesda, MD 2007.
Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582.
Rodríguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513.
Castle PE, Fetterman B, Akhtar I, et al. Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol 2009; 114:365.
Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J 2012; 6:190.
Hammer A, de Koning MN, Blaakaer J, et al. Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans. Papillomavirus Res 2019; 7:82.
Doorbar J. The human Papillomavirus twilight zone - Latency, immune control and subclinical infection. Tumour Virus Res 2023; 16:200268.
Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115:1150.
Malagón T, MacCosham A, Burchell AN, et al. Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. Clin Infect Dis 2022; 75:365.
Hammer A, Blaakaer J, de Koning MNC, et al. Evidence of latent HPV infection in older Danish women with a previous history of cervical dysplasia. Acta Obstet Gynecol Scand 2022; 101:608.
T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, Kanser Daire Başkanlığı. Serviks Kanseri Tarama Programı Ulusal Standartları.
Lees BF, Erickson BK, Huh WK (2016). Cervical cancer screening: evidence behind the guidelines. American journal of obstetrics and gynecology. 214:438-43.
Huh WK, Ault KA, Chelmow D, et al (2015). Use of primary high risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Elsevier.
Nayar R, Wilbur DC. The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)". J Low Genit Tract Dis 2015; 19:175.
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki AB, Nayar R, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-131. doi: 10.1097/LGT.0000000000000525. Erratum in: J Low Genit Tract Dis. 2020 Oct;24(4):427. doi: 10.1097/LGT.0000000000000563. PMID: 32243307; PMCID: PMC7147428.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.
Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute; Bethesda, MD 2007.
Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582.
Rodríguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513.
Castle PE, Fetterman B, Akhtar I, et al. Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol 2009; 114:365.
Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J 2012; 6:190.
Hammer A, de Koning MN, Blaakaer J, et al. Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans. Papillomavirus Res 2019; 7:82.
Doorbar J. The human Papillomavirus twilight zone - Latency, immune control and subclinical infection. Tumour Virus Res 2023; 16:200268.
Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115:1150.
Malagón T, MacCosham A, Burchell AN, et al. Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. Clin Infect Dis 2022; 75:365.
Hammer A, Blaakaer J, de Koning MNC, et al. Evidence of latent HPV infection in older Danish women with a previous history of cervical dysplasia. Acta Obstet Gynecol Scand 2022; 101:608.
T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, Kanser Daire Başkanlığı. Serviks Kanseri Tarama Programı Ulusal Standartları.
Lees BF, Erickson BK, Huh WK (2016). Cervical cancer screening: evidence behind the guidelines. American journal of obstetrics and gynecology. 214:438-43.
Huh WK, Ault KA, Chelmow D, et al (2015). Use of primary high risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Elsevier.
Nayar R, Wilbur DC. The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)". J Low Genit Tract Dis 2015; 19:175.
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki AB, Nayar R, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-131. doi: 10.1097/LGT.0000000000000525. Erratum in: J Low Genit Tract Dis. 2020 Oct;24(4):427. doi: 10.1097/LGT.0000000000000563. PMID: 32243307; PMCID: PMC7147428.
Sayfalar
9-20
Gelecek
27 Ocak 2025
Telif Hakkı (c) 2025 Akademisyen Yayınevi Kitap DOI Portalı
